LEXICON PHARMACEUTICALS, INC.
LEXICON PHARMACEUTICALS, INC. (LXRX): 4 pipeline candidates · 2 upcoming catalysts · ~39 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
39.3 months
D/E 0.33 · 0% dilution
Lead: Approved
4 candidates
2 upcoming, next in ~44d
8 buys · 0 sells (180d)
A transparent, data-derived signal for LEXICON PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$877.3M
Cash
$67.1M
Quarterly Burn
$14.7M
Runway
39.3 mo
Revenue
$21.1M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| inpefa | Approved |
| lx9851 | Preclinical |
| pilavapadin | Phase 2 |
| zynquista | Phase 3 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
132
Total value held
$169.1M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 45,056,338 | $70.3M |
| vanguard capital management llc | 19,038,334 | $29.7M |
| millennium management llc | 4,944,731 | $7.7M |
| blackrock, inc. | 3,322,219 | $5.2M |
| jane street group, llc | 3,238,938 | $5.1M |
| geode capital management, llc | 3,169,111 | $4.9M |
| susquehanna international group, llp | 2,766,264 | $4.3M |
| ubs group ag | 2,483,182 | $3.9M |
| marshall wace, llp | 2,376,304 | $3.7M |
| cibc bancorp usa inc. | 1,800,000 | $2.8M |
Showing top 10 of 132 institutional holders of LEXICON PHARMACEUTICALS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in LEXICON PHARMACEUTICALS, INC.'s pipeline?
LEXICON PHARMACEUTICALS, INC. (LXRX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is LEXICON PHARMACEUTICALS, INC.'s lead drug candidate?
LEXICON PHARMACEUTICALS, INC.'s most advanced tracked candidate is inpefa (Approved) for heart failure, type 2 diabetes mellitus, chronic kidney disease (CKD).
What is LEXICON PHARMACEUTICALS, INC.'s next catalyst?
LEXICON PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Ef" — expected August 1, 2026.
What is LEXICON PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LEXICON PHARMACEUTICALS, INC. has approximately 39.3 months of cash runway.
What is LEXICON PHARMACEUTICALS, INC.'s market capitalization?
LEXICON PHARMACEUTICALS, INC.'s market capitalization is approximately $877.3M.
Get the full picture on LEXICON PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.